Pembrolizumab-Induced Adrenal Insufficiency in Patients with Untreated Advanced Non-Small Cell Lung Cancer: A Case Series

被引：6

作者：

Sonehara, Kei ^{[1
]}

Tateishi, Kazunari ^{[1
]}

Araki, Taisuke ^{[1
]}

Komatsu, Masamichi ^{[1
]}

Akahane, Jumpei ^{[1
]}

Yamamoto, Hiroshi ^{[1
]}

Hanaoka, Masayuki ^{[1
]}

机构：

[1] Shinshu Univ, Sch Med, Dept Internal Med 1, Matsumoto, Nagano, Japan

来源：

CASE REPORTS IN ONCOLOGY | 2021年 / 14卷 / 03期

关键词：

Adrenal insufficiency; Immune-related adverse events; Non-small cell lung cancer; Pembrolizumab; ASSOCIATION;

D O I：

10.1159/000519597

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Pembrolizumab-induced adrenal insufficiency (AI) is recognized as a rare immune-related adverse event (irAE) that can be fatal if diagnosis is delayed. Clinical features of AI in patients with advanced non-small cell lung cancer (NSCLC) who received pembrolizumab as the firstline treatment were observed. Five out of 49 patients with untreated advanced NSCLC developed AI between April 2017 and February 2021. Of the 5 patients, 4 developed AI with a grade >3 and were hospitalized. The median time of the onset of AI from the start of first-line treatment was 4.63 months. All the patients improved after corticosteroid replacement therapy. The efficacy of treatment was complete response in 1 patient and partial response in 4 patients. Median progression-free survival was 37.7 months, and overall survival had not been reached. This case series revealed the efficacy of immunotherapy in AI as an irAE. (C) 2021 The Author(s). Published by S. Karger AG, Basel

引用

页码：1561 / 1566

页数：6

共 50 条

[31] Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer
Chatterjee, M.
Turner, D. C.
Felip, E.
Lena, H.
Cappuzzo, F.
Horn, L.
Garon, E. B.
Hui, R.
Arkenau, H. -T.
Gubens, M. A.
Hellmann, M. D.
Dong, D.
Li, C.
Mayawala, K.
Freshwater, T.
Ahamadi, M.
Stone, J.
Lubiniecki, G. M.
Zhang, J.
Im, E.
De Alwis, D. P.
Kondic, A. G.
Flotten, O.
ANNALS OF ONCOLOGY, 2016, 27 (07) : 1291 - 1298
[32] Carboplatin and vinorelbine in untreated locally advanced and metastatic non-small cell lung cancer
Horvath, L
Boyer, M
Clarke, S
Beale, P
Beith, J
Underhill, C
Stockler, M
Bishop, J
LUNG CANCER, 2001, 32 (02) : 173 - 178
[33] Prognostic impact of cancer cachexia in patients with advanced non-small cell lung cancer
Kimura, Madoka
Naito, Tateaki
Kenmotsu, Hirotsugu
Taira, Tetsuhiko
Wakuda, Kazushige
Oyakawa, Takuya
Hisamatsu, Yasushi
Tokito, Takaaki
Imai, Hisao
Akamatsu, Hiroaki
Ono, Akira
Kaira, Kyoichi
Murakami, Haruyasu
Endo, Masahiro
Mori, Keita
Takahashi, Toshiaki
Yamamoto, Nobuyuki
SUPPORTIVE CARE IN CANCER, 2015, 23 (06) : 1699 - 1708
[34] Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab
Oyanagi, Jun
Koh, Yasuhiro
Sato, Koichi
Mori, Keita
Teraoka, Shunsuke
Akamatsu, Hiroaki
Kanai, Kuninobu
Hayata, Atsushi
Tokudome, Nahomi
Akamatsu, Keiichiro
Nakanishi, Masanori
Ueda, Hiroki
Yamamoto, Nobuyuki
LUNG CANCER, 2019, 132 : 107 - 113
[35] The Prognostic Significance of Peripheral Blood Biomarkers in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pembrolizumab: A Clinical Study
MacDougall, Kira
Niazi, Muhammad Rafay Khan
Hosry, Jeff
Homsy, Sylvester
Bershadskiy, Alexander
ONCOLOGY-NEW YORK, 2022, 36 (03): : 156 - 161
[36] Factors associated with immunotherapy respond and survival in advanced non-small cell lung cancer patients
Wu, Yahua
Wu, Haishan
Lin, Mingqiang
Liu, Tianxiu
Li, Jiancheng
TRANSLATIONAL ONCOLOGY, 2022, 15 (01):
[37] First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status
Facchinetti, Francesco
Mazzaschi, Giulia
Barbieri, Fausto
Passiglia, Francesco
Mazzoni, Francesca
Berardi, Rossana
Proto, Claudia
Cecere, Fabiana Letizia
Pilotto, Sara
Scotti, Vieri
Rossi, Sabrina
Del Conte, Alessandro
Vita, Emanuele
Bennati, Chiara
Ardizzoni, Andrea
Cerea, Giulio
Migliorino, Maria Rita
Sala, Elisa
Camerini, Andrea
Bearz, Alessandra
De Carlo, Elisa
Zanelli, Francesca
Guaitoli, Giorgia
Garassino, Marina Chiara
Ciccone, Lucia Pia
Sartori, Giulia
Toschi, Luca
Dall'Olio, Filippo Gustavo
Landi, Lorenza
Pizzutilo, Elio Gregory
Bartoli, Gabriele
Baldessari, Cinzia
Novello, Silvia
Bria, Emilio
Cortinovis, Diego Luigi
Rossi, Giulio
Rossi, Antonio
Banna, Giuseppe Luigi
Camisa, Roberta
Di Maio, Massimo
Tiseo, Marcello
EUROPEAN JOURNAL OF CANCER, 2020, 130 : 155 - 167
[38] Safety and efficacy analysis of pembrolizumab dosing patterns in patients with advanced melanoma and non-small cell lung cancer
Kartolo, A.
Holstead, R.
Hopman, W.
Young, L.
Baetz, T.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, 28 (01) : 87 - 95
[39] Nivolumab-induced cholangitis in patients with non-small cell lung cancer: Case series and a review of literature
Izumi, Hiroki
Kodani, Masahiro
Kurai, Jun
Takeda, Kenichi
Okazaki, Ryota
Yamane, Kohei
Teruya, Yasuhiko
Yamamoto, Akihiro
Sueda, Yuriko
Yanai, Masaaki
Tanaka, Natsumi
Sakamoto, Tomohiro
Yamaguchi, Kosuke
Makino, Haruhiko
Igishi, Tadashi
Yamasaki, Akira
MOLECULAR AND CLINICAL ONCOLOGY, 2019, 11 (05) : 439 - 446
[40] Cancer cachexia as a determinant of efficacy of first-line pembrolizumab in patients with advanced non-small cell lung cancer
Fujii, Hironori
Araki, Ayumu
Iihara, Hirotoshi
Kaito, Daizo
Hirose, Chiemi
Kinomura, Motohiko
Yamazaki, Mizuki
Endo, Junki
Inui, Toshiya
Yanase, Komei
Sasaki, Yuka
Gomyo, Takenobu
Sakai, Chizuru
Kawae, Daisuke
Kitamura, Yu
Fukui, Masachika
Kobayashi, Ryo
Ohno, Yasushi
Suzuki, Akio
MOLECULAR AND CLINICAL ONCOLOGY, 2022, 16 (04)

← 1 2 3 4 5 →